/Companies

GEn1E Lifesciences

YC S19

San Francisco, US · Founded 2018 · Delaware corporation · 18 employees on LinkedIn · 18 known investors

Find your way into GEn1E Lifesciences

Each arrow is one introduction. Sign up to fill in the first one.

10,987 people can intro you to Ritu

Ask Mike Bolinder to introduce you to Ritu Lal

You →Mike · together at Mallinckrodt →Ritu

Sign up to find every way you can get introduced to GEn1E Lifesciences

  • Your email: who you already know at GEn1E Lifesciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the GEn1E Lifesciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Gen1e builds healthcare solutions supported by a network of physicians across hospitals and medical centers.

Also known as Inc.

Founders & leadership· Y Combinator alumni (S19)

GEn1E Lifesciences was founded in 2018 by Ritu Lal.

RLRitu Lal
Ritu LalFounderRitu Lal holds a doctorate in pharmaceutical sciences and pharmacology from the University of Maryland and a master's degree in management from Stanford University. As CEO and co-founder of GEn1E Lifesciences, a clinical-stage biotech company, she brings over 20 years of experience in drug development, including leadership roles in preclinical and clinical programs across neurology, inflammation, virology, pain, and oncology, with multiple FDA approvals to her name.
SB
Soujanya BhumkarExecutive

Board

NKNoor Kamruddin
Noor KamruddinBoard director
FN
Francois NaderBoard director
AL
Alan LevyBoard director

Investors · 18

Agrolimen Venturesreported

How we know: Y Combinator's founder network · Not right? Tell us

Bayside Biosciences, Inc.reportedSanta Clara

How we know: Y Combinator's founder network · Not right? Tell us

BioRock VenturesreportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

BoxOne VenturesreportedMontréal · $500K

How we know: Y Combinator's founder network · Not right? Tell us

Desire Ventures LLCreported

How we know: Y Combinator's founder network · Not right? Tell us

Endurance28reportedSan Francisco

How we know: Y Combinator's founder network · Not right? Tell us

GaingelsreportedNew York · $200K – $500K

How we know: Y Combinator's founder network · Not right? Tell us

Neue FundreportedMiami Beach · $50K – $100K

How we know: Y Combinator's founder network · Not right? Tell us

Sanno Capital GmbHreportedMunich

How we know: Y Combinator's founder network · Not right? Tell us

SP Investment Fundreported

How we know: Y Combinator's founder network · Not right? Tell us

Stanford UniversityreportedStanford

How we know: Y Combinator's founder network · Not right? Tell us

Venture Investment AssociatesreportedPeapack

How we know: Y Combinator's founder network · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$22.5M disclosed across 2 rounds · 2022–2025

▶$5.5MraisedDec 2025 · 44 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ritu LalExecutive Officer, Director
  • Francois NaderDirector
  • Alan LevyDirector
  • Noor KamruddinDirector
  • Soujanya BhumkarExecutive Officer, Director
Offering amount
$11.9M
Amount sold
$5.5M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17MraisedDec 2022 · 89 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Dr. Alan LevyDirector
  • Soujanya BhumkarDirector
  • Noor KamruddinDirector
  • Ritu LalExecutive Officer, Director
Offering amount
$18.2M
Amount sold
$17M
First sale
Dec 2022
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 10

CellChorusCellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research. The company serves biopharmaceutical companies and therapy developers seeking to understand cellular function and phenotype.
ScispotScispot provides automated sample tracking and traceability software for laboratory environments, replacing manual processes and spreadsheets with end-to-end logging and monitoring capabilities. The platform serves laboratories and research facilities seeking to improve sample management and ensure compliance.
MetoficoMetofico builds a no-code platform for analyzing large and complex datasets in life science research, allowing scientists without programming expertise to extract insights from neuroscience, behavioral tracking, and other experimental data. The tool aims to reduce the time researchers spend on data analysis tasks.
Harmonic DiscoveryHarmonic Discovery applies medicinal chemistry, cheminformatics, data science and machine learning expertise to advance drug discovery. The company is supported by investors at the intersection of technology, biology and medicine.
OrigeneOriGene develops and manufactures research and diagnostic products, including large-scale GMP antibody production, with R&D and research manufacturing operations. It serves the life sciences and biotech research market from facilities in the US and Germany.
ACXACX develops bioengineered solutions for pest control in agriculture, replacing synthetic chemicals with precision biocides. The company serves crop producers and aims to enhance food security while reducing chemical dependence and promoting biodiversity.
Generate BiomedicinesGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
GenialisGenialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
ElegenElegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.

Companies working in the same space as GEn1E Lifesciences.

In the news

Frequently asked questions

What does GEn1E Lifesciences do?
Gen1e builds healthcare solutions supported by a network of physicians across hospitals and medical centers.
Who founded GEn1E Lifesciences?
GEn1E Lifesciences was founded by Ritu Lal in 2018.
Who are GEn1E Lifesciences's investors?
GEn1E Lifesciences's investors include Clear Ventures, Y Combinator, Khosla Ventures, Harmonix Fund, Agrolimen Ventures, Bayside Biosciences, Inc., BioRock Ventures, BoxOne Ventures and 10 more.
How much funding has GEn1E Lifesciences raised?
GEn1E Lifesciences has disclosed $22.5M raised across 2 rounds.
Where is GEn1E Lifesciences headquartered?
GEn1E Lifesciences is headquartered in San Francisco, US.